Check Cap Stock Price, News & Analysis

Check-Cap Ltd. (NASDAQ: CHEK) announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs, effective immediately. Dr. Brenner-Lavie brings over 15 years of experience in clinical and regulatory affairs and will spearhead the clinical strategy for the company's groundbreaking C-Scan® technology, designed to detect colorectal polyps non-invasively. She takes over from Dr. Vardit Segal, who has held the position since 2019. This leadership change comes as the company nears the final stages of C-Scan's clinical development in the U.S.

Check-Cap Ltd. (NASDAQ: CHEK) reported its financial results for Q2 and the first half of 2021, highlighting a net loss of $3.9 million for Q2, up from $2.9 million in 2020. R&D expenses increased to $2.8 million, while G&A expenses rose to $1.1 million. The company secured $35 million in a registered direct offering on July 2, 2021, bolstering its capital position for ongoing operations and U.S. pivotal study funding until 2023. The total cash position reached $29.3 million as of June 30, 2021, down from $34 million at the end of Q1.

Check-Cap Ltd. (NASDAQ: CHEK) announced definitive agreements for a registered direct offering of 25,925,926 ordinary shares and short-term warrants, raising approximately $35 million. Each share has an offering price of $1.35, with accompanying warrants priced at $1.50. The offering is set to close around July 2, 2021. Proceeds will enhance clinical development of C-Scan®, a non-invasive colorectal cancer screening technology. Full exercise of the warrants could generate an additional $38.9 million.

Check-Cap Ltd. (NASDAQ: CHEK) announced Q1 2021 results, revealing a net loss of $3.6 million, matching the previous year's loss. The FDA approved the Investigational Device Exemption for its C-Scan® device, allowing it to start a pivotal study in the U.S., now projected for Q1 2022 due to manufacturing delays from a single-source supplier. Despite these delays, the company raised $19.2 million from warrant exercises, boosting cash and equivalents to $34 million as of March 31, 2021. R&D expenses slightly decreased to $2.4 million, while general and administrative expenses rose to $1.2 million.

Check-Cap Ltd. (NASDAQ: CHEK) reported its financial results for the fourth quarter and full year ending December 31, 2020. The company received FDA approval for its Investigational Device Exemption (IDE) for the C-Scan® colorectal cancer screening test, and was granted Breakthrough Device Designation. Check-Cap raised $25.9 million in 2020 and an additional $19.2 million in early 2021 through warrant exercises. The net loss for Q4 2020 was $3.9 million, with total R&D expenses of $2.8 million. As of December 31, 2020, cash reserves reached $18.1 million.

Check-Cap (NASDAQ: CHEK) announced FDA approval for its Investigational Device Exemption (IDE), allowing the initiation of a pivotal study for its revolutionary C-Scan® colorectal cancer screening test. This patient-friendly, preparation-free method targets individuals at average risk who are poor candidates for traditional colonoscopy. The study aims to assess C-Scan's safety and performance, with plans to enroll 250 patients across clinical sites in Israel. The FDA also granted Breakthrough Device Designation for C-Scan, emphasizing its potential in addressing unmet needs for CRC screening.

Check-Cap Ltd. (NASDAQ: CHEK) updated shareholders on its progress with the C-Scan technology, a unique screening test for colorectal cancer. In 2020, the company finalized its pivotal study design and submitted an IDE to the FDA. Manufacturing is underway, supported by a $750,000 grant from the Israel Innovation Authority. The company regained NASDAQ compliance as of January 26, 2021, and raised funds totaling approximately $34.8 million for its U.S. initiatives. The C-Scan aims to enhance screening adherence, with ongoing studies and patent protections bolstering its market presence.

Check-Cap Ltd. (NASDAQ: CHEK) submitted an Investigational Device Exemption application to the FDA for its C-Scan® pivotal study on November 18, 2020. The IDE submission marks a significant milestone as the company aims to advance its non-invasive colorectal cancer screening solution. Financially, Check-Cap reported a net loss of approximately $3.6 million in Q3 2020, similar to Q3 2019, with cash reserves of approximately $21.7 million. Research and development expenses remained stable, totaling $2.7 million. The company anticipates providing updates on study timelines in 2021.

Check-Cap Ltd. (NASDAQ: CHEK) reported financial results for Q2 2020, showing a net loss of $2.9 million, down from $3.4 million in Q2 2019. The company raised $16.3 million through offerings and has a cash position of $16.4 million as of June 30, 2020. With the Investigational Device Exemption submission to the FDA planned for late 2020 and a U.S. pivotal study beginning in 2021, Check-Cap aims to advance its C-Scan® colon cancer screening technology. Despite challenges posed by COVID-19, operations have resumed, aided by successful fundraising efforts.